USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Thermostable Reverse Transcriptases for Single Enzyme RT-PCR

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
90921
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
0839404
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
LUCIGEN CORPORATION
2905 PARMENTER ST. Middleton, WI 53562-2547
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: SBIR Phase I: Thermostable Reverse Transcriptases for Single Enzyme RT-PCR
Agency: NSF
Contract: 0839404
Award Amount: $100,000.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project proposes to improve the reliability of widely used methods for detecting and measuring trace amounts of RNA (genetic material actively made by cells and contained within certain viruses). Most current methods for detecting RNA use two different enzymes; one to convert RNA to DNA and a second to generate billions of copies by PCR amplification. This two enzyme approach has serious problems (e.g., additional manipulations, cross contamination, uneven amplification of certain genes, inaccurate amplification, and low efficiency). Alternative enzymes have been discovered and characterized at Lucigen that efficiently perform both conversion of RNA to DNA and amplification in a single reaction. However, these need to be more fully developed and characterized to replace existing methods. These candidates and others in our collection will be developed and compared to available enzymes in Phase I. Those that are superior to current enzymes will be developed for commercialization in Phase II. The broader impacts of this research include substantial cost savings in biotechnology research, increased accuracy of data, and improved reliability of diagnostic tests. Nearly $1 billion is spent annually on detecting RNA targets, and this amount is growing rapidly. This type of research is strictly dependent on the available enzymes and is compromised by their deficiencies. Improved enzymes to be developed in this SBIR project promise to greatly improve basic research, diagnostics, and drug development, and will have an important impact on human health, agriculture, and research in microbial diversity.

Principal Investigator:

Thomas W. Schoenfeld
MS
6088319011
tschoenfeld@lucigen.com

Business Contact:

Thomas W. Schoenfeld
MS
6088319011
tschoenfeld@lucigen.com
Small Business Information at Submission:

LUCIGEN CORPORATION
2120 W GREENVIEW DR STE 9 MIDDLETON, WI 53562

EIN/Tax ID: 391923306
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No